Molecular Oncology · 2020 · 13 citations · 17 references
MedicineImmunologyPharmacologyCancer ImmunologyImmunopharmacologyImmunotherapyBispecific AntibodiesBispecific Antibody TherapyCancer ImmunotherapyChemokine NetworksCytokine-based TherapyImmunotherapy For Skin CancerChemokine-based TherapyDrug Candidate OptimizationTherapeutic Targeting Of Fusion Proteins
The majority of clinically diagnosed cutaneous T‐cell lymphomas (CTCL) highly express the cell‐surface markers CC chemokine receptor 4 (CCR4) and/or CD25. Recently, we have developed diphtheria toxin‐based recombinant Ontak®‐like human IL2 fusion toxin (IL2 fusion toxin) and anti‐human CCR4 immunotoxin (CCR4 IT). In this study, we first compared the efficacy of the CCR4 IT vs IL2 fusion toxin for targeting human CD25 + CCR4 + CTCL. We demonstrated that CCR4 IT was more effective than IL2 fusion toxin. We further constructed an IL2‐CCR4 bispecific IT. The bispecific IT was significantly more effective than either IL2 fusion toxin or CCR4 IT alone. The bispecific IT is a promising novel targeted therapeutic drug candidate for the treatment of refractory and recurrent human CD25 + and/or CCR4 + CTCL.
17
Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text
Medicine, Oncology, Pharmacotherapy +13
Increased CCR4 Expression in Cutaneous T Cell Lymphoma
Katalin Ferenczi, Robert C. Fuhlbrigge, Thomas S. Kupper et al. · Journal of Investigative Dermatology · 2002 · 263 citations · Full text
Medicine, Immunology, Oncology +14